CalciMedica is a clinical-stage biopharmaceutical company developing therapeutics targeting inflammatory, immunologic, and cellular damage-related diseases. The company's primary focus is on calcium release-activated calcium (CRAC) channel inhibitors, a class of small molecule drugs designed to modulate calcium signaling pathways implicated in disease pathogenesis.
The company's lead product candidate, Auxora, is formulated as an intravenous therapy currently in clinical development for multiple acute and chronic conditions. Indications under investigation include acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, severe COVID-19 pneumonia, acute ulcerative colitis, traumatic brain injury, and allergic asthma. CalciMedica is also developing oral CRAC channel inhibitors intended for chronic inflammatory conditions, representing a potential expansion of the platform across different routes of administration and disease indications.
The company operates on a limited scale with 15 full-time employees and is headquartered in La Jolla, California. As a clinical-stage enterprise, CalciMedica currently generates no meaningful revenue and relies on capital formation to fund ongoing research and development activities. The company is incorporated in Delaware and trades on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.22 | $-1.22 | +84.1% | |
| 2023 | $-7.66 | $-7.66 | -361.4% | |
| 2022 | $-1.66 | $-1.66 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |